mRNA Vaccine
-
Phase 3 Victory for Moderna and Merck’s mRNA Cancer Vaccine Signals Paradigm Shift in Personalized Oncology
Moderna and Merck’s mRNA cancer vaccine combined with Keytruda met Phase 3 goals in melanoma, driving stock surges and paving the way for FDA filing.
-
Advancements in Colorectal Cancer: From mRNA Vaccines to New Screening Standards
Recent breakthroughs in CRC research, including CMS coverage for non-invasive testing, long-term immunotherapy success, and the launch of preventative mRNA vaccine trials, mark a pivotal shift in managing the disease.
-
FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration has reversed its initial refusal, agreeing to review Moderna’s mRNA flu vaccine application for the 2026/2027 flu season.